Menstrual blood-derived mesenchymal stem cells (MenSCs)
Cell therapy
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01496339 NCT01496339 · Type 1 Diabetes Mellitus Because patients were not randomly assigned to the stem-cell or standard-therapy group and no blinding was used, differences between the groups cannot be reliably attributed to the treatment itself. No results have been posted for this small, estimated 50-patient study. Registry: NCT01496339 | 1/2 | Glycosylated hemoglobin (HbA1c) (1 year) 2013-12 | Results not posted; external-source review pending | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.